Table 2 Comparison of outcomes between ulinastatin and control groups.
Total (n = 263) | Control (n = 84) | Ulinastatin (n = 179) | p | |
|---|---|---|---|---|
Hospital LOS (days) | 14 (6,26) | 9.5 (2,21.25) | 16 (7,27) | 0.004 |
Duration of MV (days) | 2 (0,6) | 0 (0,3) | 3 (1,7) | 0.000 |
ICU LOS (days) | 4 (2,10) | 1 (0,6) | 5 (3,11) | 0.000 |
Antibiotics duration (days) | 11 (5.5,20) | 8 (3,19.25) | 13 (7,20) | 0.003 |
Duration of vasopressor | 2 (0,4) | 2 (0,3) | 2 (0,4) | 0.603 |
28-day mortality | 101 (0.38) | 46 (0.55) | 55 (0.31) | 0.000 |
Total cost (RMB) | 37230 (19870,70690) | 19870 (8747,41140) | 46330 (26000,83500) | 0.000 |
Drug cost (RMB) | 14320 (7051,29160) | 7230 (2675,19270) | 18210 (9492,31920) | 0.000 |
